NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NVCR NovoCure

Pre-Market Trading 12-23 09:25:31 EST

30.80

+0.40

+1.32%

盘前30.72

-0.08-0.26%

09:08 EST

High31.52	Low30.33	Vol1.82M
Open30.33	D1 Closing30.40	Amplitude3.91%
Mkt Cap3.33B	Tradable Cap3.03B	Total Shares108.20M
T/O56.21M	T/O Rate1.85%	Tradable Shares98.51M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"NVCR","market":"US","secType":"STK","nameCN":"NovoCure","latestPrice":30.8,"timestamp":1734728400000,"preClose":30.4,"halted":0,"volume":1820760,"hourTrading":{"tag":"盘前","latestPrice":30.72,"preClose":30.8,"latestTime":"09:08 EST","volume":183,"amount":5658.045606000001,"timestamp":1734962889780},"delay":0,"floatShares":98512331,"shares":108201434,"eps":-1.393515,"marketStatus":"Pre-Market Trading","change":0.4,"latestTime":"12-23 09:25:31 EST","open":30.33,"high":31.52,"low":30.33,"amount":56205018.59088,"amplitude":0.039145,"askPrice":30.99,"askSize":200,"bidPrice":30.66,"bidSize":227,"shortable":3,"etf":0,"ttmEps":-1.393515,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1734964200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1443758400000,"exchange":"NASDAQ","adjPreClose":30.8,"preHourTrading":{"tag":"盘前","latestPrice":30.72,"preClose":30.8,"latestTime":"09:08 EST","volume":183,"amount":5658.045606000001,"timestamp":1734962889780},"postHourTrading":{"tag":"盘后","latestPrice":30.8005,"preClose":30.8,"latestTime":"19:51 EST","volume":273115,"amount":8411969.9067,"timestamp":1734742264649},"volumeRatio":1.264422908044827,"impliedVol":0.6812,"impliedVolPercentile":0.136},"requestUrl":"/m/hq/s/NVCR/wiki","defaultTab":"wiki","newsList":[{"id":"2492937907","title":"Novocure Ltd - Appoints Ashley Cordova as CEO Effective Jan 1, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2492937907","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492937907?lang=en_us&edition=fundamental","pubTime":"2024-12-17 19:03","pubTimestamp":1734433418,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nFWN3NI0HO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BK4534","BK4588","BK4548","NVCR","BK4585"],"gpt_icon":0},{"id":"2491109576","title":"Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?","url":"https://stock-news.laohu8.com/highlight/detail?id=2491109576","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491109576?lang=en_us&edition=fundamental","pubTime":"2024-12-15 23:00","pubTimestamp":1734274838,"startTime":"0","endTime":"0","summary":"These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?Patterson Companies, Inc.  stock rocketed 35.60%after the company announced it entered into a definitive agreement to be acquired by Patient Square Capital forapproximately$4.1 billion.NewAmsterdam Pharma Company N.V.  shares jumped 34.55% after the company announced topline data from its Phase 3 BROADWAY trial of Obicetrapib.Walgreens Boots Alliance, Inc.  gained 21.38% last week following a report from Sky News indicating that Sycamore Partners has approached various potential lenders to fund a possible acquisition of the company.NovoCure Limited  stock rose 19.49%. Piper Sandler maintained an Overweight rating and raised the price target to$42.RH  shares surged 18.60% after the company reported quarterly results and raised itsguidance. Also, Baird maintained a Neutral rating on the stock and raised its price target from $300 to $400.Pactiv Evergreen Inc.  stock upped 17.71% after the compa","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/c6vN9mcR17ruCxXcU23Kgw--~B/aD01NzY7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/a177fa4930a8f88fa1bae43e9a5b7a4a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/c6vN9mcR17ruCxXcU23Kgw--~B/aD01NzY7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/a177fa4930a8f88fa1bae43e9a5b7a4a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/walgreens-boots-alliance-alaska-air-150038320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4213","BK4008","BK4178","BK4175","BK4139","LU0321505439.SGD","BK4128","BK4500","TQQQ","NAMS","BK4548","LU2249611893.SGD","BK4539","BK4121","CRK","LU2506951792.HKD","PDCO","QID","LU0321505868.SGD","LU2294711713.HKD","STVN","TSYW.SI","RNW","BK4559","QLD","BK4136","USAW.SI","LU0823414551.USD","LU2357125470.USD",".IXIC","NVIW.SI","PTVE","WBA","BK4567","USJW.SI","NQmain","MNQmain","SQQQ","BK4534","ALK","BK4588","PSQ","BK4082","LU0823414478.USD","NVCR","BK4133","BK4585","RH"],"gpt_icon":1},{"id":"2491267203","title":"Novocure price target raised to $42 from $28 at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2491267203","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491267203?lang=en_us&edition=fundamental","pubTime":"2024-12-13 19:50","pubTimestamp":1734090626,"startTime":"0","endTime":"0","summary":"Piper Sandler raised the firm’s price target on Novocure (NVCR) to $42 from $28 and keeps an Overweight rating on the shares. The firm thinks the c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novocure-price-target-raised-to-42-from-28-at-piper-sandler?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novocure-price-target-raised-to-42-from-28-at-piper-sandler?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVCR"],"gpt_icon":0},{"id":"2491434158","title":"Novocure Ltd : Piper Sandler Raises Target Price to $42 From $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2491434158","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491434158?lang=en_us&edition=fundamental","pubTime":"2024-12-13 17:22","pubTimestamp":1734081760,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nFWN3NE088:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4534","NVCR","BK4588","BK4548","BK4082"],"gpt_icon":0},{"id":"1137565425","title":"Stock Track | NovoCure Stock Soars 5.08% on Positive Clinical Trial Results and Analyst Optimism","url":"https://stock-news.laohu8.com/highlight/detail?id=1137565425","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137565425?lang=en_us&edition=fundamental","pubTime":"2024-12-07 00:18","pubTimestamp":1733501910,"startTime":"0","endTime":"0","summary":"NovoCure's  stock soared 5.08% in Friday's intraday trading session, fueled by positive news from a late-stage clinical trial and favorable analyst reactions.The biotech company, in collaboration with Zai Lab, announced promising results from a Phase 3 clinical trial of its tumor-treating fields  therapy. The trial evaluated the therapy, administered in combination with two cancer drugs, for the treatment of unresectable, locally advanced pancreatic adenocarcinoma.The TTF therapy met its primary","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | NovoCure Stock Soars 5.08% on Positive Clinical Trial Results and Analyst Optimism","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NVCR"],"gpt_icon":0},{"id":"2489238410","title":"Why NovoCure Stock Was Winning Big This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2489238410","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489238410?lang=en_us&edition=fundamental","pubTime":"2024-12-06 20:32","pubTimestamp":1733488320,"startTime":"0","endTime":"0","summary":"The biotech's leading product did well in its most recent late-stage clinical trial.The company plans to submit for regulatory approval for the evaluated indication.","market":"us","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F800146%2Fhealthcare-professional-inspecting-charts.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F800146%2Fhealthcare-professional-inspecting-charts.jpg&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com/investing/2024/12/06/why-novocure-stock-was-winning-big-this-week/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4534","BK4588","NVCR","BK4082","BK4548","BK4585"],"gpt_icon":0},{"id":"2489073414","title":"Novocure Ltd : JP Morgan Raises Target Price to $29 From $19","url":"https://stock-news.laohu8.com/highlight/detail?id=2489073414","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489073414?lang=en_us&edition=fundamental","pubTime":"2024-12-06 18:36","pubTimestamp":1733481385,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nFWN3N70GE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4534","NVCR","BK4588","BK4548","BK4082"],"gpt_icon":0},{"id":"2489480770","title":"Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?","url":"https://stock-news.laohu8.com/highlight/detail?id=2489480770","media":"Motley Fool","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489480770?lang=en_us&edition=fundamental","pubTime":"2024-12-05 16:29","pubTimestamp":1733387340,"startTime":"0","endTime":"0","summary":"Novocure markets a battery-powered device for brain cancer patients that uses electric fields that inhibit tumor growth.A phase 3 trial recently showed a significant survival benefit for pancreatic cancer patients who applied Novocure's tumor-treating fields.In October, a Novocure device earned approval from the Food and Drug Administration to treat lung cancer.The life science industry recently gave folks diagnosed with pancreatic cancer the best news this group has received in a very long time. A new treatment option that significantly raises their chances for long-term survival could become widely available next year.Novocure  and its international partner Zai Lab  announced successful top-line results from the Panova-3 study on Dec. 2, 2024. In a nutshell, it showed that the company's electric field-generating devices can improve pancreatic cancer patients' odds of survival. Uptake could be significant because the relatively benign device produces nearly zero side effects.From the ","market":"fut","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F799708%2Fcoffee-shop-investor-getty.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F799708%2Fcoffee-shop-investor-getty.jpg&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com/investing/2024/12/05/novocure-has-alredy-doubled-in-2024-can-it-soar-hi/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4082","BK4588","BK4548","NVCR","BK4534","BK4585"],"gpt_icon":0},{"id":"2488790311","title":"Novocure Stock Earns 96 RS Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2488790311","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488790311?lang=en_us&edition=fundamental","pubTime":"2024-12-04 03:51","pubTimestamp":1733255460,"startTime":"0","endTime":"0","summary":"Novocure sees its Relative Strength Rating hit the elite 90-plus level.","market":"sg","thumbnail":"https://www.investors.com/wp-content/uploads/2017/05/IRU1-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2017/05/IRU1-150x150.jpg"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/news/novocure-stock-earns-96-rs-rating/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["RS","NVCR"],"gpt_icon":0},{"id":"2488923421","title":"NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals","url":"https://stock-news.laohu8.com/highlight/detail?id=2488923421","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488923421?lang=en_us&edition=fundamental","pubTime":"2024-12-03 22:56","pubTimestamp":1733237760,"startTime":"0","endTime":"0","summary":"Novocure LimitedNVCR announced meeting the primary endpoint of overall survival  in a late-stage study, which evaluated the use of Tumor Treating Fields  therapy concomitantly with chemotherapy regimen as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma. Shares of the company gained 49% on Monday in response to the encouraging news.TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The phase III PANOVA-3 evaluated the efficacy and safety ofTTFields therapy in combination with standard-of-care  chemotherapy  to treat pancreatic cancer patients. The enrolled patient population was randomized equally into two arms to receive either the combo regimen or SoC chemotherapy alone  and followed for atleast 18 months.Pancreatic cancer is one of the deadliest cancers and the third leading cause of cancer-related deaths in the United States. While overall cancer rates remaining stable or declining, pancreatic","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kHYuj_GDhroF7BEQsCcsVA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kHYuj_GDhroF7BEQsCcsVA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvcr-stock-ttfields-therapy-meets-145600302.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","LU0456855351.SGD","LU0985481810.HKD","GILD","SG9999002224.SGD","LU1894683348.USD","IE00B19Z3B42.SGD","LU2468319806.SGD","LU0170899867.USD","SG9999013999.USD","LU0225284248.USD","BK4533","LU1066051498.USD","BK4578","IE00BSNM7G36.USD","IE000M9KFDE8.USD","BK4592","LU1023059063.AUD","BK4139","BK4534","OS","PFE","LU1066053197.SGD","SG9999011175.SGD","BK4082","BK4532","BK4566","LU1571399168.USD","LU1585245621.USD","NVCR","BK4581","LU0109394709.USD","SG9999002232.USD","BK4097","LU0889565916.HKD","LU1839511570.USD","BK4550","IE00BLSP4239.USD","BK4548","SG9999001176.SGD","RHHBY","LU0234570918.USD","LU2087621335.USD","LU1057294990.SGD","03165","BK4007","IE00BLSP4452.SGD","IE0002270589.USD","IE00BZ1G4Q59.USD","LU0058720904.USD"],"gpt_icon":1},{"id":"2488115909","title":"Novocure Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2488115909","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488115909?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:36","pubTimestamp":1733229360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NVCR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2024 07:36 ET (12:36 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR"],"gpt_icon":0},{"id":"2488919647","title":"Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2488919647","media":"TipRanks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488919647?lang=en_us&edition=fundamental","pubTime":"2024-12-03 20:17","pubTimestamp":1733228263,"startTime":"0","endTime":"0","summary":"Zai Lab  and Novocure  announced that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival, or mOS, versus control. PANOVA-3 evaluated the use of Tumor Treating Fields, or TTFields, therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma. In the intent-to-treat population, patients treated with TTFields therapy concomitant with gemcitabine and nab-paclitaxel had an mOS of 16.20 months compared to 14.16 months in patients treated with gemcitabine and nab-paclitaxel alone, a statistically significant 2.0-month improvement. The survival rate benefit for patients treated with TTFields therapy increased over time with a 13% improvement in the overall survival rate at 12 months and a 33% improvement in survival rate at 24 months. TTFields therapy was well-tolerated, and safety was consistent with prior clinical stud","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/VfFShRbSXeKd1NWnCc3B2Q--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/5c9a5f191a1b61dffcdf2f63fbd4912c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/VfFShRbSXeKd1NWnCc3B2Q--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/5c9a5f191a1b61dffcdf2f63fbd4912c"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/zai-lab-novocure-announce-panova-121743561.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zai-lab-novocure-announce-panova-121743561.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4139","BK4548","NVCR","BK4526","BK4534","ZLAB","BK4082","BK4531","BK4588"],"gpt_icon":0},{"id":"2488048966","title":"Novocure Launches 49% After Pancreatic Cancer Treatment Succeeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2488048966","media":"Blockhead","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488048966?lang=en_us&edition=fundamental","pubTime":"2024-12-03 05:23","pubTimestamp":1733174630,"startTime":"0","endTime":"0","summary":"Novocure stock catapulted early Monday after the company's cancer-treating device succeeded in a study of patients with pancreatic cancer.","market":"hk","thumbnail":"https://www.investors.com/wp-content/uploads/2021/02/Stock-novocure-01-shutt-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2021/02/Stock-novocure-01-shutt-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/novocure-stock-tumor-treating-fields-pancreatic-cancer/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4534","BK4588","NVCR","BK4548","BK4585","BK4082"],"gpt_icon":0},{"id":"2488198661","title":"U.S. Small Caps Close Mixed As Novocure Lead, Archer Aviation Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2488198661","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488198661?lang=en_us&edition=fundamental","pubTime":"2024-12-03 05:20","pubTimestamp":1733174400,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of small-cap companies were mixed Monday, as the Russell 2000 Index closed flat, while the S&P Small Cap 600 Index was up 0.3%.Among companies with a market value of $1 billion to $6.7 billion, Novocure Ltd. was the best performer during the session, surging 49%, followed by PTC Therapeutics Inc., which jumped 19%. Nebius Group N.V. Cl A shares jumped 17%, Fastly Inc. Cl A surged 16%, and shares of Wolfspeed Inc. surged 16%.Archer Aviation Inc. was the biggest laggard, dropping 24%, followed by shares of Pharvaris N.V., which dropped 13%. Shares of Lemonade Inc. dropped 11%, Janux Therapeutics Inc. shares tumbled 11%, and Intuitive Machines Inc. Cl A tumbled 11%.Major U.S. stock indexes closed mixed Monday with the Nasdaq Composite Index adding 1.0%. Meanwhile, the S&P 500 Index gained 0.2%, and the Dow Jones Industrial Average dropped 0.3%.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NVCR","BK4588","BK4585","BK4534","BK4548"],"gpt_icon":0},{"id":"2488584601","title":"Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2488584601","media":"Benzinga","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488584601?lang=en_us&edition=fundamental","pubTime":"2024-12-03 01:44","pubTimestamp":1733161460,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/24/12/42272541/dow-dips-150-points-ism-manufacturing-pmi-tops-estimates","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4539","IE00BD6J9T35.USD","QID","BK4142","LU1720051108.HKD","PSQ","LU2360107325.USD","LU1854103824.USD","LU0124384867.USD","ON","LU2298322129.HKD","SQQQ","LU1861215975.USD","MOND","LU1861214812.USD","LU1861219969.SGD","LU2357305700.SGD",".IXIC","UPST","LU1548497426.USD","BK4170","BK4512","LU0348723411.USD","NVCR","LU1978683503.SGD","BK4585","BK4548","BK4141","PCOM","LU1861220033.SGD","LU1720051017.SGD","BK4122","BK4166","TQQQ","NQmain","LU0724618433.USD","SNTI","BK4561","RVMD","LU1854104046.USD","SMCI","BK4082","MNQmain","BK4534","IE00BZ199S13.USD","QLD","LU0053671581.USD","BK4139"],"gpt_icon":1},{"id":"2488601889","title":"HC Wainwright Adjusts NovoCure Price Target to $38 From $30, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2488601889","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488601889?lang=en_us&edition=fundamental","pubTime":"2024-12-03 01:38","pubTimestamp":1733161087,"startTime":"0","endTime":"0","summary":"Price: 29.65, Change: +9.61, Percent Change: +47.95","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVCR"],"gpt_icon":0},{"id":"2488060076","title":"Update: NovoCure's Shares Rise as Pancreatic Cancer Trial Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2488060076","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488060076?lang=en_us&edition=fundamental","pubTime":"2024-12-03 01:09","pubTimestamp":1733159383,"startTime":"0","endTime":"0","summary":"NovoCure's  shares rose more than 41% in recent Monday trading after the company and Zai Lab  said that their phase 3 trial evaluating TTFields along with gemcitabine and nab-paclitaxel as a treatment for unresectable, locally advanced pancreatic adenocarcinoma achieved its primary endpoint, demonstrating a \"statistically significant\" improvement in median overall survival.NovoCure  plans regulatory filings in the US, EU, Japan, and other major markets, while Zai Lab plans to file for regulatory approval in China, the companies said.Price: 28.83, Change: -0.02, Percent Change: -0.07","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4526","ZLAB","NVCR","BK4585","BK4082","BK4534","BK4548","BK4139","BK4531"],"gpt_icon":0},{"id":"2488606715","title":"Novocure Price Target Raised to $38.00/Share From $30.00 by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2488606715","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488606715?lang=en_us&edition=fundamental","pubTime":"2024-12-03 01:06","pubTimestamp":1733159160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NVCR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 02, 2024 12:06 ET (17:06 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR"],"gpt_icon":0},{"id":"2488054726","title":"Leerink Partners Adjusts NovoCure Price Target to $33 From $28, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2488054726","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488054726?lang=en_us&edition=fundamental","pubTime":"2024-12-03 00:40","pubTimestamp":1733157614,"startTime":"0","endTime":"0","summary":"Price: 27.64, Change: +7.60, Percent Change: +37.92","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVCR"],"gpt_icon":0},{"id":"2488603148","title":"Novocure Ltd : Leerink Partners Raises Target Price to $33 From $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2488603148","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488603148?lang=en_us&edition=fundamental","pubTime":"2024-12-03 00:12","pubTimestamp":1733155962,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nFWN3N30Y1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4082","BK4534","NVCR","BK4585","BK4548"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novocure.com","stockEarnings":[{"period":"1week","weight":-0.0781},{"period":"1month","weight":0.8268},{"period":"3month","weight":0.765},{"period":"6month","weight":0.6151},{"period":"1year","weight":1.3071},{"period":"ytd","weight":1.063}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.007929},{"month":2,"riseRate":0.444444,"avgChangeRate":0.011207},{"month":3,"riseRate":0.555556,"avgChangeRate":-0.012375},{"month":4,"riseRate":0.444444,"avgChangeRate":0.086397},{"month":5,"riseRate":0.777778,"avgChangeRate":0.143619},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.022202},{"month":7,"riseRate":0.555556,"avgChangeRate":0.033773},{"month":8,"riseRate":0.555556,"avgChangeRate":0.014898},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.029067},{"month":10,"riseRate":0.222222,"avgChangeRate":-0.10093},{"month":11,"riseRate":0.7,"avgChangeRate":0.085037},{"month":12,"riseRate":0.5,"avgChangeRate":0.075749}],"exchange":"NASDAQ","name":"NovoCure","nameEN":"NovoCure"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NovoCure(NVCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NovoCure,NVCR,NovoCure股票,NovoCure股票老虎,NovoCure股票老虎国际,NovoCure行情,NovoCure股票行情,NovoCure股价,NovoCure股市,NovoCure股票价格,NovoCure股票交易,NovoCure股票购买,NovoCure股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NovoCure(NVCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}